Search

Your search keyword '"Hao, Chunfang"' showing total 125 results
Start Over Author "Hao, Chunfang"
125 results on '"Hao, Chunfang"'

2. Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial

Author

Yan, Min, Ouyang, Quchang, Sun, Tao, Niu, Limin, Yang, Jin, Li, Li, Song, Yuhua, Hao, Chunfang, Chen, Zhanhong, Liu, Zhenzhen, Lv, Huimin, Zhang, Mengwei, Liu, Liping, Yang, Xiaohong, Xiao, Huawu, Gao, Zhichao, Li, Xiaorui, Dong, Fangyuan, Zhang, Lingxiao, Dong, Danfeng, Chen, Xiuchun, Qiao, Jianghua, Zhang, Guifang, Zeng, Huiai, Wang, Jing, Sun, Huihui, Feng, Yajing, Chen, Yuting, and Xia, Fangzhou

Published
2024
Full Text
View/download PDF

4. A non-inferiority, phase III trial of gemcitabine plus capecitabine versus gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer.

Author

Liu, Xiaodong, Zhao, Weipeng, Jia, Yongsheng, Shi, Yehui, Wang, Xu, Li, Shufen, Zhang, Pin, Wang, Chen, Hao, Chunfang, and Tong, Zhongsheng

Abstract

Background: Gemcitabine plus capecitabine (GX) shows survival benefit and manageable safety in patients with advanced triple-negative breast cancer (TNBC) but there is a paucity of phase III trial evidence. We aimed to compare the efficacy and safety of GX with gemcitabine plus carboplatin (GC) as first-line treatment for patients with advanced TNBC and validate the prognostic value of tumor-infiltrating lymphocytes (TILs). Methods: Patients with advanced TNBC were randomly assigned 1:1 to receive gemcitabine (1000 mg/m2) on days 1 and 8 plus oral capecitabine (1000 mg/m2 twice a day) on days 1–14, or gemcitabine (1000 mg/m2) on days 1 and 8 plus carboplatin area under curve 2 on days 1 and 8. The primary endpoint was progression-free survival (PFS). TILs were analyzed by immunohistochemistry. The margin used to establish non-inferiority was 1.2. Results: In all, 187 patients were randomly assigned, with 93 in GX and 94 in GC. Median PFS was 6.1 months in the GX arm compared with 6.3 months in the GC arm. The hazard ratio for PFS was 1.148, and a 95% CI was 0.856–1.539, exceeding the non-inferiority margin of 1.2. The median overall survival (OS) was 21.0 months in the GX arm compared with 21.5 months in the GC arm. The safety profile for the GX regimen was superior to the GC regimen, especially regarding hematological toxicity. Patients with high CD8+ TILs had significantly longer PFS and OS compared with patients with low CD8+ TILs. In the high CD8+ TIL group, the GC arm had prolonged PFS and OS compared with the GX arm. Conclusion: The trial did not meet the prespecified criteria for the primary endpoint of PFS in patients with advanced TNBC. Moreover, the GC regimen showed better efficacy compared with the GX regimen in patients with high CD8+ TILs. However, the GX regimen should be considered in patients who cannot tolerate hematological toxicity. Trial registration: ClinicalTrials.gov identifier: NCT02207335. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial

Author

Yan, Min, Ouyang, Quchang, Sun, Tao, Niu, Limin, Yang, Jin, Li, Li, Song, Yuhua, Hao, Chunfang, Chen, Zhanhong, Orlandi, Armando, Ishii, Naohiro, Takabe, Kazuaki, Franceschini, Gianluca, Ricci, Francesco, Verschraegen, Claire, Liu, Zhenzhen, Zhang, Mengwei, Lv, Huimin, Liu, Liping, Yang, Xiaohong, Xiao, Huawu, Gao, Zhichao, Li, Xiaorui, Dong, Fangyuan, Chen, Xiuchun, Qiao, Jianghua, and Zhang, Guifang

Published
2022
Full Text
View/download PDF

6. Comparison of the efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: a subgroup analysis of a randomized, double-blinded phase III study

Author

Liu, Yaxin, primary, Zhang, Ruyan, additional, Wang, Xiaojia, additional, Di, Lijun, additional, Chen, Zhendong, additional, Wang, Jingfen, additional, Sun, Tao, additional, Li, Qingshan, additional, Cheng, Jing, additional, Zhang, Qingyuan, additional, Wang, Xiuwen, additional, Wang, Junye, additional, Gu, Kangsheng, additional, Wei, Shihong, additional, Zhang, Shuqun, additional, Wang, Xiangcai, additional, Sun, Ping, additional, Hao, Chunfang, additional, Zang, Aimin, additional, Han, Cuicui, additional, Li, Yujie, additional, Kang, Xiaoyan, additional, Li, Yanlin, additional, and Li, Huiping, additional

Published
2024
Full Text
View/download PDF

9. Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients

Author

Wang,Shuling, Chen,Yuqin, Li,Weidong, Hao,Chunfang, Zhang,Li, Zhao,Weipeng, Shi,Yehui, Tong,Zhongsheng, Wang,Shuling, Chen,Yuqin, Li,Weidong, Hao,Chunfang, Zhang,Li, Zhao,Weipeng, Shi,Yehui, and Tong,Zhongsheng

Abstract

Shuling Wang,1,2,&ast; Yuqin Chen,1– 3,&ast; Weidong Li,2,4,&ast; Chunfang Hao,1,2 Li Zhang,1,2 Weipeng Zhao,1,2 Yehui Shi,1,2 Zhongsheng Tong1,2 1Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China; 2Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, People’s Republic of China; 3Department of Respiratory Center, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, People’s Republic of China; 4Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Yehui Shi; Zhongsheng Tong, Email shiyehui@tjmuch.com; tongzhongsheng_on@163.comBackground: The purpose of this study was to investigate the therapeutic efficacy and prognosis of serum HER2 (sHER2) in patients with advanced breast cancer.Methods: We analyzed the sHER2 levels of 200 patients with advanced breast cancer receiving first or second line treatment, the tissue HER2 (tHER2) level was also analyzed. Indicators of therapeutic efficacy and prognosis were objective response rate (ORR), disease control rate (DCR), and time to progression (TTP).Results: The baseline sHER2 level was high in 132 patients and low in 68 patients. The high level of sHER2 is correlated with molecular subtype (p=0.016), visceral metastasis (p< 0.001), liver metastasis (p< 0.001), tissue HER-2 (tHER2) (p=0.001), and, among tHER2-low tumors (59 patients), the baseline sHER2 high level was associated with a higher proportion of brain metastasis. The ORR of patients wi

Published
2024

10. Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China

Author

Wu, Xinyu, primary, Jin, Nan, additional, Gao, Hongfei, additional, Yan, Min, additional, Chen, Qianjun, additional, Sun, Tao, additional, Hao, Chunfang, additional, Zhao, Yanxia, additional, Han, Xinhua, additional, Pan, Yueyin, additional, Huang, Xiang, additional, Li, Wei, additional, Wang, Kun, additional, and Yin, Yongmei, additional

Published
2023
Full Text
View/download PDF

11. Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2‐low and HER2‐zero breast cancer among Chinese females

Author

Zheng, Lu, primary, Zhang, Yunmeng, additional, Wang, Zhipeng, additional, Wang, Huan, additional, Hao, Chunfang, additional, Li, Chenyang, additional, Zhao, Yanrui, additional, Lyu, Zhangyan, additional, Song, Fangfang, additional, Chen, Kexin, additional, Huang, Yubei, additional, and Song, Fengju, additional

Published
2023
Full Text
View/download PDF

14. Abstract P1-12-11: Real-world incidence and management of diarrhea secondary to pyrotinib in patients with HER-2 positive breast cancer

Author

Liu, Hong, primary, Ma, Li, additional, Wang, Xu, additional, Chang, Xinzhong, additional, Yu, Qi, additional, Huang, Qingfeng, additional, Hao, Chunfang, additional, Liu, Jun, additional, Zhao, Jing, additional, Li, Shufen, additional, Tong, Zhongsheng, additional, Shi, Yehui, additional, Lu, Ning, additional, Zhao, Weipeng, additional, Wang, Tong, additional, Cao, Xuchen, additional, Wang, Chen, additional, Liu, Juntian, additional, Zhao, Ying, additional, Zhang, Lina, additional, Guo, Baoliang, additional, Wang, Xin, additional, Di, Xu, additional, Gao, Chunhui, additional, Liu, Zongzhan, additional, Sun, Shuo, additional, and Li, Linwei, additional

Published
2023
Full Text
View/download PDF

15. Additional file 5 of Establishing extended pluripotent stem cells from human urine cells

Author

Hao, Chunfang, Chu, Shilong, Quan, Xiongzhi, Zhou, Tiancheng, Shi, Junjie, Huang, Xiaofen, Wu, Guangming, Tortorella, Micky Daniel, and Pei, Duanqing

Abstract

Additional file 5: Figure S5. Clinical drug K115 could be used as a Rock inhibitor for subculture of pluripotent stem cells. A Day 1 of H9, hUC-iPSC-2, hUC-iPSC-3 passaging by mTeSR1 with Thiazovivin. B Day 4 of H9, hUC-iPSC-2, hUC-iPSC-3 passaging. C Karyotype analysis of H9, hUC-iPSC-2, hUC-iPSC-3 or the 10th generation by Thiazovivin. D Day 1 of H9, hUC-iPSC-2, hUC-iPSC-3 passaging by mTeSR1 with K115. E Day 4 of H9, hUC-iPSC-2, hUC-iPSC-3 passaging. F Karyotype analysis of H9, hUC-iPSC-2, hUC-iPSC-3 for the 10th generation by K115. Scale bar: 100 μm.

Published
2023
Full Text
View/download PDF

16. Additional file 1 of Establishing extended pluripotent stem cells from human urine cells

Author

Hao, Chunfang, Chu, Shilong, Quan, Xiongzhi, Zhou, Tiancheng, Shi, Junjie, Huang, Xiaofen, Wu, Guangming, Tortorella, Micky Daniel, and Pei, Duanqing

Abstract

Additional file 1: Figure S1. The signaling pathway were reanalyzed between human zygote and hESC. The signaling pathway were reanalyzed between Zygote and ESC P10 from Tang’s single cell RNA-SEQ data. Red color: up-regulation of signaling pathway, Blue color: down-regulation of signaling pathway, fold change > 2, p < 0.05.

Published
2023
Full Text
View/download PDF

17. Additional file 3 of Establishing extended pluripotent stem cells from human urine cells

Author

Hao, Chunfang, Chu, Shilong, Quan, Xiongzhi, Zhou, Tiancheng, Shi, Junjie, Huang, Xiaofen, Wu, Guangming, Tortorella, Micky Daniel, and Pei, Duanqing

Abstract

Additional file 3: Figure S3. The process of integration-free iPSCs induction from human urine-derived cells. A The process of human urine cells was inducted to be iPSCs. pEP4 EO2S ET2Kand pCEP4-miR302-367were electroporated into human urine cells, and the process of cell shape changing. B The monoclonal hUC-iPSCs by 4I induction medium and karyotype analysis. C The monoclonal hUC-iPSCs by R5 induction medium and karyotype analysis. Scale bar: 100 μm.

Published
2023
Full Text
View/download PDF

18. Additional file 2 of Establishing extended pluripotent stem cells from human urine cells

Author

Hao, Chunfang, Chu, Shilong, Quan, Xiongzhi, Zhou, Tiancheng, Shi, Junjie, Huang, Xiaofen, Wu, Guangming, Tortorella, Micky Daniel, and Pei, Duanqing

Abstract

Additional file 2: Figure S2. The major cell death pathways of pluripotent stem cell and orbitrap protein analysis. A Pluripotent stem cells after passage for 24 h. B Amplified cell death picture. C Heatmap of orbitrap analysis: from Left to Right: H9, supernatant death cells of H9S, hUC-iPSC-2, supernatant death cells of U2S. D The major cell death ways of pluripotent stem cells. E Venn diagram of up-regulation and down-regulation of protein expression in H9S U2S contrast with H9 and U2.

Published
2023
Full Text
View/download PDF

19. Additional file 4 of Establishing extended pluripotent stem cells from human urine cells

Author

Hao, Chunfang, Chu, Shilong, Quan, Xiongzhi, Zhou, Tiancheng, Shi, Junjie, Huang, Xiaofen, Wu, Guangming, Tortorella, Micky Daniel, and Pei, Duanqing

Abstract

Additional file 4: Figure S4. DsRed cells in mTeSR1 and OCM175 culture medium and different culture conditions. A H9ds and U2ds O-IPSCs were cultured in mTeSR1. B H9ds and U2ds O-IPSCs were cultured in OCM175. C H9ds and U2ds O-IPSCs were cultured in mTeSR1 and OCM175 without changing medium for 2 days.

Published
2023
Full Text
View/download PDF

24. A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer

Author

Li, Shufen, Meng, Wenjing, Zhang, Jibo, Xie, Xiaojuan, Hao, Chunfang, Jia, Yongsheng, and Tong, Zhongsheng

Subjects
Diseases, Care and treatment, Research, Product development, Clinical trials -- Research, Anthracyclines -- Product development -- Research, Cancer research, Chemotherapy -- Research, Breast cancer -- Research -- Care and treatment, Cancer metastasis -- Care and treatment -- Research
Published
2020

28. Real‐world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2− advanced breast cancer.

Author

Hao, Chunfang, Bai, Xuedong, Zhang, Jie, Meng, Wenjing, and Tong, Zhongsheng

Subjects
*THERAPEUTIC use of antineoplastic agents, *DIPHOSPHONATES, *KIDNEYS, *ACADEMIC medical centers, *CANCER patients, *CREATINE, *TREATMENT effectiveness, *BONE metastasis, *PATIENT safety, *HORMONE receptor positive breast cancer
Abstract

Objective: Our study evaluated the renal safety of abemaciclib plus endocrine therapy (ET) with bisphosphonate as a treatment option for hormone receptor positive, human epidermal growth factor receptor 2 (HER‐2) negative (HR+/HER2−) advanced breast cancer (ABC), especially with bone metastasis. Methods: Data were collected from HR+/HER2− ABC patients who received abemaciclib with ET between March 2021 and May 2022 in a single medical center in China. We performed an analysis of the change in serum creatine (Cr) and creatine clearance (CrCl), time to first abnormal Cr value, and Common Terminology Criteria for Adverse Events grade of increased creatinine. Results: A total of 210 patients were included in the final analysis, with a median age of 56 years and a median weight of 65 kg. Any grade laboratory‐assessing increased Cr occurred in 87.1% of patients, while CrCl rarely went down to 30 ml/min. Associations between start dose with grade of increased Cr and menopausal status with alert value, which is defined as creatinine clearance <30 ml/min, were indicated. Conclusion: This study shows that abemaciclib combined with bisphosphonate would be safe for renal function in HR+/HER2− ABC patients with bone metastases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. MicroRNA-449 targets histone deacetylase 1 to regulate the proliferation, invasion, and apoptosis of synovial fibroblasts in rheumatoid arthritis

Author

Guo, Jiangtao, primary, Cao, Xuqing, additional, Zhao, Wei, additional, Zhu, Hong, additional, Ma, Xiaoli, additional, Hao, Chunfang, additional, Wu, Lili, additional, Zhang, Mingzhu, additional, Yang, Yashan, additional, Zhao, Jingtian, additional, Chen, Kunting, additional, and Yin, Zhe, additional

Published
2021
Full Text
View/download PDF

33. Cytokine levels and pathological characteristics of a patient with severe coronavirus disease 2019: a case report

Author

Kang, Kai, primary, Gao, Yang, additional, Zhao, Mingyan, additional, Fei, Dongsheng, additional, Ye, Ming, additional, Gao, Yan, additional, Yang, Wei, additional, Wang, Changsong, additional, Liu, Haitao, additional, Chang, Guangping, additional, Kang, Xianxin, additional, Luo, Yunpeng, additional, Du, Xue, additional, Qi, Jiping, additional, Tian, Lin, additional, Zhou, Min, additional, Hao, Chunfang, additional, and Yu, Kaijiang, additional

Published
2021
Full Text
View/download PDF

38. Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

Author

Jiang, Zefei, primary, Song, Erwei, additional, Wang, Xiaojia, additional, Wang, Haibo, additional, Wang, Xiang, additional, Wu, Jiong, additional, Yin, Yongmei, additional, Zhang, Qingyuan, additional, Chen, Jiayi, additional, Che, Wenyan, additional, Chen, Xiaoyuan, additional, Chen, Zhanhong, additional, Fu, Peifen, additional, Geng, Cuizhi, additional, Guo, Baoliang, additional, Hao, Chunfang, additional, He, Yingjian, additional, Jin, Feng, additional, Liao, Ning, additional, Li, Nanlin, additional, Liu, Jian, additional, Liu, Qiang, additional, Liu, Yunjiang, additional, Liu, Yueping, additional, Ma, Jie, additional, Nie, Jianyun, additional, Pan, Yueyin, additional, Song, Chuangui, additional, Sun, Tao, additional, Wang, Kun, additional, Wang, Shu, additional, Wang, Tao, additional, Wang, Xin, additional, Wang, Biyun, additional, Wang, Shusen, additional, Wang, Yongsheng, additional, Xu, Ling, additional, Yan, Min, additional, Yan, Ying, additional, Yuan, Peng, additional, Yang, Junlan, additional, Zhang, Fan, additional, Zhang, Jun, additional, Zhang, Shaohua, additional, Zeng, Xuan, additional, Li, Jianbin, additional, and Xu, Fengrui, additional

Published
2020
Full Text
View/download PDF

39. Real-world clinical analysis and overall survival-related biomarker of breast cancer (BC) patients under 35 years old.

Author

Yu, Jinpu, primary, Li, Yang, additional, Li, Xuesong, additional, Yang, Beibei, additional, Wang, Shuaibing, additional, Lu, Su, additional, Shi, Yehui, additional, Hao, Chunfang, additional, Zhang, Geng, additional, Wang, Xiaohong, additional, Ma, Jie, additional, Liu, Hong, additional, Shi, Xiaoliang, additional, Qiao, Huidong, additional, and Liu, Zhenzhen, additional

Published
2020
Full Text
View/download PDF

41. Microcalcification and BMP-2 in breast cancer: correlation with clinicopathological features and outcomes

Author

Zhang,Li, Hao,Chunfang, Wu,Yansheng, Zhu,Yuying, Ren,Yulin, and Tong,Zhongsheng

Subjects
skin and connective tissue diseases, OncoTargets and Therapy
Abstract

Li Zhang,1,* Chunfang Hao,1,* Yansheng Wu,2 Yuying Zhu,1 Yulin Ren,1 Zhongsheng Tong1 1Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China; 2Department of Maxillofacial and Otorhinolaryngology Head and Neck Surgery, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China *These authors contributed equally to this work Background: Microcalcification is a very important diagnostic information in breast cancer. The purpose of this study was to determine the relationship of clinicopathological features and prognosis of breast cancer with microcalcification and to detect biomarkers related to the possible mechanisms of microcalcifications.Patients and methods: All 529 subjects with microcalcifications were selected from patients who had been examined using breast mammography. The control group did not have detectable microcalcifications, and was matched in a ratio of 1:3. The clinicopathological factors, progression-free survival (PFS), and overall survival were evaluated by SPSS.Results: There was a significant difference in tumor size between the two groups, with larger tumors in the calcification group than the control group, and the proportion of patients in the calcification group with tumors of >5 cm was 20.4% vs 17.2% in the control group (P=0.041). The proportion of patients with lymph node metastasis in the calcification group was higher than that of the control group (35% vs 27.9%, P=0.027). The recurrence rate in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) patients with microcalcification was higher than that in the control group (P=0.035 and 0.044). BMP-2 expression was higher in breast cancer tissues, especially in breast cancer tissues with microcalcifications. The recurrence rate in the BMP-2(+) group was higher than that in the BMP-2(-) group both in DCIS and IDC (P=0.044 and 0.049). Microcalcifications and the positive expression of BMP-2 were independent factors affecting the PFS of the breast cancer patients.Conclusion: Through the analysis of this study, it was found that the prognosis of the patients with microcalcification was relatively poor. BMP-2 was highly expressed in the breast cancer with microcalcification and was associated with poor prognosis. Keywords: breast cancer, microcalcification, BMP-2, mammography, immunohistochemistry prognosis

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results